
Auteur G. BRIGHAM
|
Documents disponibles écrits par cet auteur (2)

L. AMASS ; W. LING ; T. E. FREESE ; C. REIBER ; J. J. ANNON ; A. J. COHEN ; D. McCARTY ; M. S. REID ; L. S. Jr BROWN ; C. CLARK ; ZIEDONIS D. M. ; J. KREJCI ; STINE S. ; T. WINHUSEN ; G. BRIGHAM ; D. BABCOCK ; MUIR J. A. ; B. J. BUCHAN ; T. HORTON | 2004
Dans American Journal on Addictions (Vol.13, Suppl.1, May-June 2004) Article : PériodiqueIn October 2002, the US Food and Drug Administration approved buprenorphine-naloxone (Suboxone) sublingual tablets as an opioid dependence treatment available for use outside traditionally licensed opioid treatment programs. The NIDA Center for [...]
W. LING ; P. JACOBS ; M. HILLHOUSE ; A. HASSON ; C. THOMAS ; T. FREESE ; S. SPARENBORG ; D. McCARTY ; R. WEISS ; A. SAXON ; A. COHEN ; M. STRAUS ; G. BRIGHAM ; D. LIU ; P. McLAUGHLIN ; B. TAI | 2010
Dans Journal of Substance Abuse Treatment (Vol.38, Suppl.1, June 2010) Article : PériodiqueThe National Institute on Drug Abuse (NIDA) established the National Drug Abuse Treatment Clinical Trials Network (CTN) in 1999 to bring researchers and treatment providers together to develop a clinically relevant research agenda. Initial CTN e[...]